LSIPR webinar: CAR-T trends show increased filing for narrower tech, says HGF partner
05-09-2019
posteriori / iStockphoto.com
Novartis has teamed up with a clinical-stage biopharmaceutical firm in efforts to bring the Swiss company’s proprietary cancer treatment to patients in China.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Novartis, Cellular Biomedicine Group, CAR T therapy, oncology, cancer treatment, Kymriah, China, licensing agreement, collaboration, biopharmaceutical
